Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000568605

Apexbio Technology LLC Scopolamine-HBr-triH2O
SDP

Catalog No. 5000568605
Encompass_Preferred

Scopolamine HBr trihydrate (CAS No 6533-68-2) is utilized in biomedical research primarily within the pharmacological and neuroscientific fields It is derived from the plant family Solanaceae acting as a non-selective muscarinic antagonist By targeting the muscarinic acetylcholine receptors it effectively blocks acetylcholine action impacting neurotransmission pathways Its in vitro activity is generally observed in the nanomolar to low micromolar range making it a potent compound for detailed studies Scopolamine HBr trihydrate is commonly applied in cell models and animal studies to investigate neurological conditions such as memory impairment and motion sickness It is also used in drug screening to evaluate the efficacy of new therapeutic agents targeting cognitive disorders Experimental concentrations typically depend on the specific research design employed by investigators

Catalog No. 50-005-68605 Supplier Apexbio Technology LLC Supplier No. C641925
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Scopolamine HBr trihydrate (CAS No 6533-68-2) is utilized in biomedical research primarily within the pharmacological and neuroscientific fields It is derived from the plant family Solanaceae acting as a non-selective muscarinic antagonist By targeting the muscarinic acetylcholine receptors it effectively blocks acetylcholine action impacting neurotransmission pathways Its in vitro activity is generally observed in the nanomolar to low micromolar range making it a potent compound for detailed studies Scopolamine HBr trihydrate is commonly applied in cell models and animal studies to investigate neurological conditions such as memory impairment and motion sickness It is also used in drug screening to evaluate the efficacy of new therapeutic agents targeting cognitive disorders Experimental concentrations typically depend on the specific research design employed by investigators

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.